Anthem Biosciences
The model puts Anthem Biosciences at ₹823 per share — 11.6% below today's price.
Model estimate · 2 yrs of reported financials · dated 16 Nov 2026
All values are mathematically derived from financial models and do not constitute buy, sell, or hold recommendations. Models rely on historical data and assumptions that may not reflect future outcomes. StockRank is not a registered investment advisor — always do your own research before making investment decisions.
DCF model history
ANTHEM is pricier than usual.It was this expensive or more on just 11% of days in the past 5 years.
ANTHEM is pricier than usual
Pricier than on 88% of days over 5 years
After days like today
Past results do not predict future returns.
360° view
The takeaway
A profitable, low-leverage CRDMO and specialty-ingredients business with strong margins and returns, but high reported valuation multiples and a market-implied path below the current price are the main trade-offs.
↗ Strengths
- Reported profitability is strong, with operating and net margins in the high double digits and returns on capital and equity in the high teens to high twenties.
- The balance sheet shows low leverage, substantial cash relative to borrowings and very high interest coverage.
- Promoters hold about 71% with no reported pledging; one-year price performance was positive.
↘ Risks to watch
- Valuation multiples are high on reported earnings, book value and EBITDA, and the retrospective market-implied path sits below the observed price.
- Five-year growth measures are unavailable, and the projected book return on invested capital exceeds 100%, raising questions about operating-capital scope and reinvestment economics.
Anthem Biosciences is a contract research, development and manufacturing organization serving pharmaceutical and biotechnology clients across drug discovery, development and commercial manufacturing for small molecules and biologics. It also sells specialty fermentation-based ingredients such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Reported segments cover CRDMO services and specialty ingredients, with revenue spread across Europe, North America, India and the rest of Asia.
Key metrics
Latest reported · price-based figures use the EOD quote5 scoring axes
How cheaply the stock is priced relative to earnings, assets, and cash flows vs peers.
17/100How cheaply the stock is priced relative to earnings, assets, and cash flows vs peers.
- Market value of equity relative to reported shareholder equity. Asset quality, profitability and accounting practices affect how the ratio should be read.
- 17.36×
- Share price relative to earnings per share over the trailing 12 months. Growth, risk and one-off earnings can affect this ratio; it is not meaningful when earnings are nonpositive.
- 85.95×
- P/E divided by the earnings-growth rate used in the ratio. Its meaning depends on that growth period and whether growth is sustainable.
- 4.54×
- Enterprise value relative to trailing 12-month earnings before interest, tax, depreciation and amortisation. It includes debt in valuation but does not account for capital spending or all cash needs.
- 62.13×
- Reported annual operating cash flow as a percentage of current market value of equity. This is before capital spending, so it is not free cash flow.
- 1.60%
- Percentage difference between the saved valuation estimate and its reference share price. It depends on assumptions and is not a forecast return.
- -12.16%
Profitability, capital efficiency, and consistency of cash generation.
94/100Profitability, capital efficiency, and consistency of cash generation.
- Net profit as a percentage of revenue over the trailing 12 months. Tax, financing and one-off items can affect the margin.
- 30.00%
- Operating profit as a percentage of revenue over the trailing 12 months. It reflects operating profitability before financing and tax, and varies by industry.
- 41.37%
- A count of nine accounting checks covering profitability, financial position and operating efficiency. More checks passed does not guarantee future performance, and the measure is less suited to financial businesses.
- 7 / 9
- Operating profit relative to the capital used in the business. It indicates capital efficiency, but industry capital needs and accounting values affect comparisons.
- 27.56%
- Net profit relative to shareholder equity. Debt or a small equity base can raise this ratio without improving the underlying business.
- 19.45%
- Operating cash flow divided by common net profit for the same annual period. It shows how earnings translate into operating cash, but working-capital timing can move the ratio.
- 1.43×
- The share of observed annual periods with positive common earnings within the last ten years. It describes profit frequency, not the size or stability of those profits.
- 100.00%
- The middle annual return on capital employed from the five-year history. It reduces the influence of a single unusual year but can hide recent changes.
- 25.38%
Revenue and earnings growth rates across multiple time horizons.
69/100Revenue and earnings growth rates across multiple time horizons.
- Operating cash flow growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- 40.27%
- Earnings-per-share growth expressed as a compounded annual rate over three years. Changes in share count and one-off profits can affect the rate.
- 15.39%
- Net profit growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- 15.39%
- Net profit growth expressed as a compounded annual rate over 5 years. It smooths year-to-year changes and does not predict future growth.
- —
- Revenue change from the same quarter a year earlier. It reduces seasonal differences, but a weak comparison period can amplify growth.
- 8.00%
- Revenue growth expressed as a compounded annual rate over 3 years. It smooths year-to-year changes and does not predict future growth.
- 26.20%
- Revenue growth expressed as a compounded annual rate over 5 years. It smooths year-to-year changes and does not predict future growth.
- —
Balance sheet strength, leverage, and financial stability.
97/100Balance sheet strength, leverage, and financial stability.
- Cash and cash equivalents divided by borrowings. It shows how much borrowing is covered by reported cash, which may not all be freely available.
- 5.38×
- Current assets divided by current liabilities. It describes short-term balance-sheet coverage, but inventories and receivables may not turn into cash quickly.
- 5.54×
- Borrowings relative to shareholder equity. More borrowing can increase financing risk; the ratio has different meaning for lenders and is not useful with nonpositive equity.
- 0.02×
- Earnings available to cover interest expense, expressed as a multiple. It indicates interest-payment capacity but does not cover principal repayments or all cash needs.
- 143.54×
- The share of promoter holdings pledged as collateral. Pledging can create financing pressure if collateral values fall; zero pledging does not remove other risks.
- 0.00%
- The percentage of shares held by promoters. Ownership concentration can align interests but does not by itself establish governance quality.
- 71.40%
Recent price moves and changes in earnings and institutional ownership.
83/100Recent price moves and changes in earnings and institutional ownership.
- Change in the share of equity held by domestic institutional investors over one year, in percentage points. It describes ownership changes, not the cash they invested or future returns.
- 4.90 pp
- The latest quarterly operating margin minus the average of the preceding four quarters, in percentage points. It describes a margin change, not percentage growth in profit.
- 6.57 pp
- Net profit change from the same quarter a year earlier. One-off items and a small comparison-period profit can make the percentage unusually large.
- 21.93%
- Revenue change from the same quarter a year earlier. It reduces seasonal differences, but a weak comparison period can amplify growth.
- 8.00%
- Share-price change over one year. Past price performance does not predict future returns.
- 38.01%
- Share-price change over three years in total, not per year. Past price performance does not predict future returns.
- —
Peer Companies
BiotechnologyQuarterly Results
₹ Cr · per share in ₹| Particulars | Dec '24 | Mar '25 | Jun '25 | Sep '25 | Dec '25 | Mar '26 | Jun '26 | Sep '26 |
|---|---|---|---|---|---|---|---|---|
| − Revenue | ||||||||
| Revenue | 497.81 | 483.20 | 540.21 | 550.03 | 423.15 | 610.94 | 418.22 | 594.03 |
| Revenue Growth YoY | — | — | 59.54% | 4.78% | -15.00% | 26.44% | -22.58% | 8.00% |
| − Profitability | ||||||||
| Operating Profit | 159.51 | 195.19 | 191.49 | 217.90 | 157.20 | 267.22 | 150.57 | 271.50 |
| OPM % | 32.04% | 40.40% | 35.45% | 39.62% | 37.15% | 43.74% | 36.00% | 45.70% |
| Profit Before Tax | 161.05 | 178.31 | 186.25 | 229.60 | 130.47 | 277.92 | 144.58 | 296.37 |
| − Bottom Line | ||||||||
| Net Profit | 124.33 | 82.62 | 135.79 | 173.43 | 92.82 | 189.76 | 119.94 | 211.46 |
| Net Profit Growth YoY | — | — | 64.84% | 7.10% | -25.35% | 129.67% | -11.67% | 21.93% |
| EPS | 2.22 | 1.48 | 2.43 | 3.09 | 1.65 | 3.38 | 2.13 | 3.75 |
Income Statement
Annual · ₹ Cr · per share in ₹| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| − Revenue | ||||
| Revenue | 1,056.92 | 1,419.37 | 1,844.55 | 2,124.33 |
| Revenue Growth | — | 34.29% | 29.96% | 15.17% |
| − Expenses & Profitability | ||||
| Operating Profit | 428.89 | 504.98 | 670.84 | 833.81 |
| OPM % | 37.82% | 34.05% | 34.75% | 36.57% |
| Profit Before Tax | 497.30 | 477.32 | 656.87 | 824.24 |
| − Bottom Line | ||||
| Net Profit | 385.18 | 367.31 | 451.26 | 591.79 |
| Profit Growth | — | -4.64% | 22.86% | 31.14% |
| EPS | 6.75 | 6.48 | 8.07 | 10.55 |
Balance Sheet
Annual · ₹ CrLiabilities shown exclude shareholders’ funds and other equity. Assets equal liabilities plus equity.
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| − Equity | ||||
| Shareholders' Funds | 1,740.67 | 1,924.66 | 2,409.86 | 3,042.52 |
| − Liabilities | ||||
| Total Borrowings | 125.07 | 232.53 | 108.96 | 51.06 |
| Total Current Liabilities | 163.87 | 338.63 | 326.23 | 325.71 |
| Total Liabilities | 273.79 | 473.46 | 397.72 | 386.77 |
| − Assets | ||||
| Fixed Assets | 612.97 | 827.21 | 1,001.98 | 1,047.58 |
| Investments | 499.03 | 471.62 | 433.07 | 1,007.47 |
| Cash & Equivalents | 342.85 | 184.36 | 316.98 | 274.88 |
| Total Current Assets | 1,323.17 | 1,481.55 | 1,736.72 | 1,803.14 |
| Total Assets | 2,014.46 | 2,398.11 | 2,807.58 | 3,429.29 |
Cash Flow
Annual · ₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| − Cash Flows | ||||
| Cash from Operations | 305.98 | 140.15 | 418.34 | 844.48 |
| Cash from Investing | -376.02 | -221.46 | -152.11 | -701.62 |
| Cash from Financing | 63.98 | -77.18 | -133.60 | -40.00 |
| Net Cash Flow | -6.06 | -158.49 | 132.62 | 102.60 |
| − Cash Position | ||||
| Closing Cash | 342.85 | 184.36 | 316.98 | 274.88 |
Shareholding Pattern
Promoters hold 71.4% of Anthem Biosciences, more than half. Since 18 Jul 2025, public shareholders’ share has fallen from 20.2% to 12.7%, while Indian institutions’ share has risen from 3.6% to 12.1%.
| Holder | 18 Jul ’25 | Sep ’25 | Dec ’25 | Mar ’26 | Jun ’26 | Sep ’26 |
|---|---|---|---|---|---|---|
| Promoters | 74.7% | 74.7% | 74.7% | 74.7% | 71.4% | 71.4% |
| Foreign institutions FII | 1.5% | 1.7% | 1.4% | 1.3% | 2.6% | 3.8% |
| Indian institutions DII | 3.6% | 7.2% | 7.6% | 11.6% | 13.5% | 12.1% |
| Public | 20.2% | 16.4% | 16.3% | 12.5% | 12.5% | 12.7% |
Darker shading marks the quarters when that holder owned more.
Dividend History
Anthem Biosciences paid ₹2.00 per share in dividends in the last 12 months, in one payment. That is 0.21% of the share price, its dividend yield.
Per share, by year
- 2026so far ₹2.00per share one payment
By calendar year of the ex-date. Records start Jun 2026.




